Royal Bank of Canada
GRCL

Royal Bank of Canada’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Royal Bank of Canada’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,030
Closed -$251K – 7842
2023
Q4 		$251K Buy
25,030
+25,000
+83,333% +$113K ﹤0.01% 4909
2023
Q3 		$0 Hold
30
– – ﹤0.01% 7819
2023
Q2 		$0 Sell
30
-85
-74% -$238 ﹤0.01% 7828
2023
Q1 		$0 Buy
115
+70
+156% +$146 ﹤0.01% 7654
2022
Q4 		$0 Sell
45
-62
-58% -$190 ﹤0.01% 7933
2022
Q3 		$0 Sell
107
-1,493
-93% -$4.86K ﹤0.01% 8042
2022
Q2 		$9K Buy
+1,600
New +$4.97K ﹤0.01% 6440

Royal Bank of Canada's GRCL Position: Q1 2024 in Review

Royal Bank of Canada sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 25,030 shares — an estimated $251K sold.

Royal Bank of Canada first reported a position in GRCL in Q2 2022 and held it in 7 quarters. The position peaked at $251K in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

  • Royal Bank of Canada reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 25,030 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $251K.
  • Royal Bank of Canada first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q2 2022 and held it in 7 quarters.
  • Royal Bank of Canada's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $251K in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Royal Bank of Canada's 13F filing for Q1 2024, filed 15 May 2024.